Single Center, Open-Label, Single-Sequence, Within-Subject Study In Two Cohorts Of Healthy Male Subjects Comparing Single-Dose Pharmacokinetics Of Fedovapagon Alone And In Combination With A CYP3A4 Inhibitor, Itraconazole, Or A CYP3A4 Inducer, Rifampicin

Trial Profile

Single Center, Open-Label, Single-Sequence, Within-Subject Study In Two Cohorts Of Healthy Male Subjects Comparing Single-Dose Pharmacokinetics Of Fedovapagon Alone And In Combination With A CYP3A4 Inhibitor, Itraconazole, Or A CYP3A4 Inducer, Rifampicin

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2015

At a glance

  • Drugs Fedovapagon (Primary) ; Itraconazole; Rifampicin
  • Indications Nocturia
  • Focus Pharmacokinetics
  • Sponsors Vantia Therapeutics
  • Most Recent Events

    • 29 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 16 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top